Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
07 nov. 2022 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
29 juil. 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety...
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
24 août 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
Tempol: A potential home treatment for COVID-19 (https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19). Trial to begin shortly. SAN DIEGO, Aug. 24, 2021 (GLOBE...
Adamis Announces Agreement to Sell Portion of US Compounding Business
04 août 2021 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a significant portion of the...
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
11 juin 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of...
Adamis Provides Update on ZIMHI™
09 juin 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s...
Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19
07 juin 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the...
Adamis Pharmaceuticals Provides Business Update
01 juin 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
28 mai 2021 16h04 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
17 mai 2021 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be...